2 unchanged sentences
None of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as such terms are defined in Items 408(a) and 408(c) of Regulation S-K, respectively) during the quarterly period covered by this report.
−Removed: Strategic Restructuring and Executive Retention
−Removed: Refer to Note 11 “Subsequent Events” for further details around the restructuring and retention remuneration awarded to the Company’s executive officers.
Exhibit Description
8 unchanged sentences
(Exhibit 3.1)
−Removed: Consulting Agreement, effective as of August 29, 2024, by and between the Registrant and Kamal Hamed
−Removed: Separation Agreement, dated July 30, 2024, by and between the Registrant and Kama Hamed.
+Added: 2017 Stock Incentive Plan, as Amended
+Added: (Exhibit 10.1)
+Added: Amended and Restated Employment Agreement, dated June 13, 2023, by and between the Registrant and Satyavrat Shukla
+Added: (Exhibit 10.3)
+Added: Interim Period Agreement, dated January 10, 2025, by and between the Registrant and Satyavrat Shukla
+Added: (Exhibit 10.1)
+Added: Retention Letter Agreement, dated November 13, 2024, by and between the Registrant and Satyavrat Shukla
+Added: (Exhibit 10.12)
+Added: Separation Agreement, dated April 28, 2025, by and between the Registrant and Satyavrat Shukla
+Added: Separation Agreement, dated July 30, 2024 by and between the Registrant and Kamal Hamed, M.D.
+Added: (Exhibit 10.2)
+Added: Employment Agreement, dated January 1, 2020, by and between the Registrant and Timothy Keutzer
+Added: (Exhibit 10.12)
+Added: Retention Letter Agreement, dated November 13, 2024, by and between the Registrant and Timothy Keutzer
+Added: (Exhibit 10.19)
+Added: Employment Agreement, dated October 31, 2023 by and between the Registrant and Esther Rajavelu
+Added: (Exhibit 10.1)
+Added: Amended and Restated Employment Agreement, dated April 28, 2025, by and between the Registrant and Esther Rajavelu
+Added: Interim Period Agreement, dated January 10, 2025, by and between the Registrant and Esther Rajavelu
+Added: (Exhibit 10.2)
+Added: Retention Letter Agreement, dated November 13, 2024, by and between the Registrant and Esther Rajavelu
+Added: (Exhibit 10.22)
Consulting Agreement, effective as of August 5, 2024, by and between the Registrant and John C.
Pottage, Jr., M.D.
+Added: (Exhibit 10.3)
+Added: Amended and Restated Consulting Agreement, effective as of January 29, 2025, by and between the Registrant and John C.
+Added: Pottage, Jr., M.D.
+Added: (Exhibit 10.28)
+Added: Amendment 3 to Exclusive License Agreement, dated March 4, 2024, by and between the Registrant and GlaxoSmithKline Intellectual Property (No.
+Added: (Exhibit 10.4)
Amendment 4 to Exclusive License Agreement, dated October 28, 2024, by and between the Registrant and GlaxoSmithKline Intellectual Property (No.
−Removed: Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
−Removed: Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
+Added: (Exhibit 10.4)
+Added: Spero Therapeutics, Inc.
+Added: Insider Trading Policy, effective as of June 5, 2023
+Added: (Exhibit 19.1)
+Added: Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Certification pursuant to 18 U.S.C.
13 unchanged sentences
SPERO THERAPEUTICS, INC.
−Removed: November 14, 2024
−Removed: /s/ Satyavrat Shukla
−Removed: Satyavrat Shukla
−Removed: President and Chief Executive Officer
−Removed: (Principal Executive Officer)
−Removed: November 14, 2024
/s/ Esther Rajavelu
Esther Rajavelu
−Removed: Chief Financial Officer, Chief Business Officer and Treasurer
−Removed: (Principal Financial Officer and Principal Accounting Officer)
+Added: President, Chief Executive Officer, Chief Financial Officer and Treasurer
+Added: (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.